Abnormality of liver function
Conditions
Interventions
Sponsors
Tokai University School of Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Outpatients whom meeting the following requirements will be included. 1) Outpatients have shown at least one higher value of three biomarkers of liver function than below criterion values for 2 month; ALT: 40 IU/L or more AST: 35 IU/L or more Gamma-GTP: 80 IU/L or more 2) Outpatients diagnosed as fatty liver using ultrasonography
Exclusion criteria
Exclusion criteria: We will exclude outpatients 1) with serious liver diseases and suspected acute liver failure. 2) with viral hepatitis 3) with serious heart problem 4) with renal dysfunction (serum creatinine > 2.0 mg/dL) 5) with bile duct cancer 6) without capacity of self- management of drug therapy 7) with serious diseases in their life and then judged unsuitable for this study 8) with risk of allergy 9) with suspected infectious diseases 10) who participated in other clinical trials within 2 months. 11) who habitually consume higher amount of alcohol (> avg 60 g alcohol/day) 12) who are judged unsuitable for this study by principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biomarkers of liver function such as AST, ALT and gamma-GTP will be measured as primary endpoint. If at least one of those is statistically improved in comparison with before and after the intervention with sulforaphane, the result will be considered as effective. | — |
Secondary
| Measure | Time frame |
|---|---|
| As secondary endpoints, following items will be evaluated; physical parameters, blood biochemical values, biomarkers of oxidative stress and inflammation, adipocytokines, diagnosis of fatty liver (determined with ultrasound scanning and FibroScan-CAP), and subjective scores of quality of life. | — |
Countries
Japan
Contacts
Public ContactMasahiro Kikuchi
Tokai University School of Medicine Dept. of Gastroenterology
Outcome results
None listed